187 related articles for article (PubMed ID: 32189245)
1. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
Desnick RJ; Banikazemi M; Wasserstein M
Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
[TBL] [Abstract][Full Text] [Related]
3. A case of female Fabry disease revealed by renal biopsy.
Aratani S; Yamakawa H; Suzuki S; Otsuka T; Sakai Y; Shimizu A; Tsuruoka S
CEN Case Rep; 2020 Feb; 9(1):24-29. PubMed ID: 31542871
[TBL] [Abstract][Full Text] [Related]
4. A classic variant of Fabry disease in a family with the M296I late-onset variant.
Hirashio S; Kagawa R; Tajima G; Masaki T
CEN Case Rep; 2021 Feb; 10(1):106-110. PubMed ID: 32902816
[TBL] [Abstract][Full Text] [Related]
5. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
[TBL] [Abstract][Full Text] [Related]
6. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
7. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
8. Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry disease.
Shimohata H; Maruyama H; Miyamoto Y; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2017 Nov; 6(2):148-151. PubMed ID: 28593486
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
[TBL] [Abstract][Full Text] [Related]
10. [Fabry Disease: Pathogenesis, Clinical Symptoms, and Treatment with Enzyme Replacement Therapy].
Sawai S
Brain Nerve; 2015 Sep; 67(9):1099-108. PubMed ID: 26329150
[TBL] [Abstract][Full Text] [Related]
11. Treatment of fabry disease: current and emerging strategies.
Rozenfeld P; Neumann PM
Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
[TBL] [Abstract][Full Text] [Related]
12. Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.
Ito S; Ogura M; Kamei K; Matsuoka K; Warnock DG
Pediatr Nephrol; 2016 Aug; 31(8):1369-73. PubMed ID: 27129690
[TBL] [Abstract][Full Text] [Related]
13. Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy.
Yonishi H; Namba-Hamano T; Hamano T; Hotta M; Nakamura J; Sakai S; Minami S; Yamamoto T; Takahashi A; Kobayashi W; Maeda I; Hidaka Y; Takabatake Y; Sakai N; Isaka Y
Nephrol Dial Transplant; 2021 Dec; 37(1):53-62. PubMed ID: 33367839
[TBL] [Abstract][Full Text] [Related]
14. A Renal Variant of Fabry Disease Diagnosed by the Presence of Urinary Mulberry Cells.
Shimohata H; Ogawa Y; Maruyama H; Hirayama K; Kobayashi M
Intern Med; 2016; 55(23):3475-3478. PubMed ID: 27904112
[TBL] [Abstract][Full Text] [Related]
15. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
16. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
17. Renal complications of Fabry disease in children.
Najafian B; Mauer M; Hopkin RJ; Svarstad E
Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
[TBL] [Abstract][Full Text] [Related]
20. Renal complications of Fabry disease.
Basic-Jukic N; Kes P; Coric M; Basic-Kes V
Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
